Search clinical trials for: Raltegravir

Total 250 results

Kirby Institute

Completed

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
ViiV Healthcare

Completed

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
St Stephens Aids Trust

Completed

Raltegravir and Ezetimibe PK Study

HIV

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

HIV Infections | Tuberculosis

South Africa
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

HIV Infections

Austria
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. (AVIATOR)

HIV | Hypercholesterolaemia

Netherlands
Universidad Peruana Cayetano Heredia
Merck Sharp & Dohme LLC

Completed

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

HTLV-I Infections | Tropical Spastic Paraparesis

Peru
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study (NEARQD)

HIV Infections

Spain
Queen Mary University of London
Merck Sharp & Dohme LLC

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis

United Kingdom
The Miriam Hospital
Merck Sharp & Dohme LLC; Tufts Medical Center

Completed

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

HIV Infections | HIV | Hypertriglyceridemia | Hyperlipidemia

United States
University of California, Los Angeles
University Health Network, Toronto; Merck Sharp & Dohme LLC; Tufts University; Vanderbilt... and other collaborators

Completed

Raltegravir Therapy for Women With HIV and Fat Accumulation

HIV Infections | Lipodystrophy

United States, Canada
Stanford University

Completed

RAL-eve Study: Raltegravir Substitution Study

HIV Infections

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) (GRAPPA)

HIV Infections

Netherlands
National Institute of Neurological Disorders and...

Completed

Raltegravir for HAM/TSP

HTLV-I Infection

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Human T-cell Leukemia Virus Type 1 Infection
Community Research Initiative of New England

Completed

BRAVO: Background Regimen of Raltegravir on Virologic Outcome (BRAVO)

HIV Infections

United States
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

HIV Infections | HIV-1

Spain
University of Rochester
Merck Sharp & Dohme LLC

Completed

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women

HIV Infections

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

HIV Infections

Spain
Germans Trias i Pujol Hospital

Completed

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

HIV Infections

Spain
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Raltegravir Intensification in HIV-infected Patients

HIV Infections

United States
The University of Texas Health Science Center,...

Unknown

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

HIV Infection

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC

Completed

Renal Transplantation and Raltegravir in HIV-Infected Patients (ANRS153TREVE)

HIV-1 Infection | Chronic Renal Insufficiency

France
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Terminated

A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV (HANDral)

Human Immunodeficiency Virus (HIV) | HIV Associated Neurocognitive Disorders (HAND)

Australia
Boehringer Ingelheim

Completed

Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

Healthy

Germany
UMC Utrecht
Merck Sharp & Dohme LLC

Unknown

RAltegravir Switch STudy: Effects on Endothelial Recovery (RASSTER)

HIV Infection | Endothelial Dysfunction

Netherlands
University of North Carolina, Chapel Hill

Completed

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

Pharmacokinetics

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
New Mexico Cancer Care Alliance
American Cancer Society, Inc.

Completed

Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Fondazione Penta UK
UCL Great Ormond Street Institute of Child Health

Recruiting

Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

HIV Infections

Spain, Switzerland, United Kingdom, Belgium, Italy, Romania, Russian Federation
The HIV Netherlands Australia Thailand Research...
Chulalongkorn University; National Healthcare Group Pte Ltd, Singapore

Completed

Pharmacokinetics of Low Dose Raltegravir

HIV Infections

Thailand
University of Miami
Merck Sharp & Dohme LLC

Terminated

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

HIV

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Human Immunodeficiency Virus
Pfizer

Completed

Drug Interaction Study Between Raltegravir And UK-453,061

Healthy Volunteers

United States
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

HIV Infections

United States, Thailand, Puerto Rico, Brazil, South Africa

Search clinical trials for: Raltegravir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations